BUZZ-Gilead Sciences Inc: Sovaldi sales slip

Tue Oct 28, 2014 6:17pm EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

** U.S. drugmaker's shares down about 4 pct at $110.70 in extended trading

** Sales of $84,000 hepatitis C drug Sovaldi dipped as doctors and patients awaited a recently approved combination pill

** Q3 Sovaldi sales $2.8 billion, below the average Wall Street estimate of $2.97 billion, according to Deutsche Bank

** Up to Monday's close, Gilead shares had gained about 51 pct this year